A Relative Bioavailability Study of Bupropion HCI 150 mg Sustained-Release Tablets Under Fasting Conditions
Primary Purpose
Depression
Status
Completed
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
Bupropion HCI ER Tablets, 150 mg; EON Labs Inc.
WELLBUTRIN SR (Bupropion HCI) Sustained-Release Tablets, 150 mg; GlaxoSmithKline
Sponsored by

About this trial
This is an interventional treatment trial for Depression
Eligibility Criteria
Inclusion Criteria:
- No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.
Exclusion Criteria:
- Positive test results for HIV or hepatitis B or C.
- Treatment for drug or alcohol dependence.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
1
2
Arm Description
Bupropion HCI ER Tablets, 150 mg
WELLBUTRIN SR (Bupropion HCI) Sustained-Release Tablets, 150 mg
Outcomes
Primary Outcome Measures
Bioequivalence according to US FDA timelines
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00864981
Brief Title
A Relative Bioavailability Study of Bupropion HCI 150 mg Sustained-Release Tablets Under Fasting Conditions
Official Title
A Relative Bioavailability Study of Bupropion HCI 150 mg Sustained-Release Tablets Under Fasting Conditions
Study Type
Interventional
2. Study Status
Record Verification Date
March 2009
Overall Recruitment Status
Completed
Study Start Date
September 2005 (undefined)
Primary Completion Date
October 2005 (Actual)
Study Completion Date
October 2005 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Sandoz
4. Oversight
5. Study Description
Brief Summary
The purpose of this study is to demonstrate the relative bioequivalence of Bupropion HCI 150 mg SR Tablets under fasting conditions.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Depression
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
32 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Experimental
Arm Description
Bupropion HCI ER Tablets, 150 mg
Arm Title
2
Arm Type
Active Comparator
Arm Description
WELLBUTRIN SR (Bupropion HCI) Sustained-Release Tablets, 150 mg
Intervention Type
Drug
Intervention Name(s)
Bupropion HCI ER Tablets, 150 mg; EON Labs Inc.
Intervention Type
Drug
Intervention Name(s)
WELLBUTRIN SR (Bupropion HCI) Sustained-Release Tablets, 150 mg; GlaxoSmithKline
Primary Outcome Measure Information:
Title
Bioequivalence according to US FDA timelines
Time Frame
29 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.
Exclusion Criteria:
Positive test results for HIV or hepatitis B or C.
Treatment for drug or alcohol dependence.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Shirley A Kennedy, M.D.
Organizational Affiliation
Novum Pharmaceutical Research Services
Official's Role
Principal Investigator
12. IPD Sharing Statement
Learn more about this trial
A Relative Bioavailability Study of Bupropion HCI 150 mg Sustained-Release Tablets Under Fasting Conditions
We'll reach out to this number within 24 hrs